Overview

An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the exposure to prasugrel's active metabolite and the pharmacodynamic effects of prasugrel treatment in people with Sickle Cell Disease (SCD).
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Daiichi Sankyo Co., Ltd.
Treatments:
Prasugrel Hydrochloride